Lifecore Biomedical, INC \de\ Form 4 insider transactions

Director Christopher S. Kiper of Lifecore Biomedical, Inc. was granted 25,907 restricted stock units as compensation for board service.

Director Nelson Obus has been granted 25,907 restricted stock units, bringing his total beneficial ownership to 164,100 shares.

Director Jason Aryeh acquired 25,907 restricted stock units in Lifecore Biomedical, Inc., increasing his total beneficial ownership to nearly 70,000 shares.

Director Joshua Schechter has been granted 25,907 restricted stock units as part of his compensation, increasing his total beneficial ownership to 133,080 shares.

Director Matthew E. Korenberg has been granted 25,907 restricted stock units, increasing his total stake in Lifecore Biomedical to nearly 70,000 shares.

Lifecore Biomedical Director Humberto Calheiros Antunes has been granted 25,907 restricted stock units as part of director compensation, increasing his total holdings to 72,967 shares.

Director Paul Harold Johnson acquired 25,907 shares of Lifecore Biomedical, Inc. common stock via restricted stock unit conversion.

Director Katrina Houde Lovas was granted 25,907 restricted stock units in Lifecore Biomedical, Inc.

Lifecore Biomedical's CEO, Paul Josephs, reported a transaction involving common stock, impacting his beneficial ownership.

Chief Legal & Administration Officer Thomas D. Salus reported the withholding of 24,645 shares to cover tax obligations.

Lifecore Biomedical, Inc. reported an equity grant of 30,000 restricted stock units to its Chief Legal & Administration Officer, Thomas D. Salus, vesting in three years.

LifeCore Biomedical CFO Ryan Lake disposed of 22,932 common shares at $7.71 each to cover tax obligations related to RSU vesting.

Lifecore Biomedical, Inc. Director Nelson Obus acquired 19,506 restricted stock units, increasing his direct beneficial ownership to 138,193 shares.

Christopher S. Kiper, a director and 10% owner of Lifecore Biomedical, Inc., along with affiliated entities, reported the acquisition of 19,506 restricted stock units and detailed their collective beneficial ownership of the company's common stock.

Paul Harold Johnson, a Director at Lifecore Biomedical, Inc., acquired 19,506 restricted stock units, increasing his direct beneficial ownership to 44,060 shares.

LIFECORE BIOMEDICAL, INC. Director Jason Aryeh acquired 19,506 shares of common stock through a restricted stock unit grant, increasing his total beneficial ownership to 44,060 shares.

Lifecore Biomedical, Inc. Director Matthew E. Korenberg was granted 19,506 restricted stock units, increasing his direct beneficial ownership to 44,060 shares and aligning his interests with long-term shareholder value.

Lifecore Biomedical, Inc. Director Humberto Calheiros Antunes is reported to acquire 19,506 shares of common stock through a restricted stock unit grant on July 15, 2025, increasing his beneficial ownership to 47,060 shares.

Lifecore Biomedical, Inc. Director Joshua Schechter reported the future acquisition of 19,506 restricted stock units, which will increase his direct beneficial ownership to 107,173 shares.

Katrina Houde Lovas, a Director at Lifecore Biomedical, Inc., acquired 19,506 shares of common stock through a restricted stock unit grant, increasing her total beneficial ownership to 109,412 shares.

LifeCore Biomedical's Chief Legal & Administration Officer, Thomas D. Salus, acquired 37,000 shares of common stock through the vesting of performance-based restricted stock units, with a portion withheld for tax obligations.

LifeCore Biomedical's Chief Financial Officer, Ryan David Lake, acquired 75,000 shares of common stock through the vesting of performance-based restricted stock units and subsequently disposed of 32,806 shares to cover tax withholding obligations.

LifeCore Biomedical, Inc. CEO and Director Paul Josephs acquired 150,000 shares of common stock through the vesting of performance-based restricted stock units, indicating the company achieved a stock price milestone.

Aron R. English, a Director and 10% owner of LIFECORE BIOMEDICAL, INC., along with affiliated entities, reported the sale of over 1.3 million shares of common stock across multiple transactions in late May 2025.

Paul Josephs, CEO of LifeCore Biomedical, disposed of 21,532 shares of common stock on May 20, 2025, to satisfy tax withholding obligations related to RSU vesting.

Aron English, along with related entities, reports the sale of Lifecore Biomedical shares at an average price of $7.0012.

Aron R. English, along with related entities, reports the sale of Lifecore Biomedical (LFCR) shares, reducing their holdings.

22NW Fund, LP, along with related entities and Aron English, reported the sale of Lifecore Biomedical (LFCR) common stock in multiple transactions between May 5th and May 7th, 2025.

Thomas D. Salus, Chief Legal & Administration Officer of Lifecore Biomedical, reports acquiring common stock and performance-based restricted stock units.

LifeCore Biomedical's CEO, Paul Josephs, purchased 17,000 shares of common stock at $5.74 per share on January 8, 2025.